Carpenter Technology (CRS): Aerospace Was 120% Of The Growth. Is CRS a Buy? episode artwork

EPISODE · Aug 3, 2026 · 15 MIN

Carpenter Technology (CRS): Aerospace Was 120% Of The Growth. Is CRS a Buy?

from Charged Alpha Stock Encyclopedia · host Colton Thomas

Carpenter Technology Corporation (CRS) Q4 FY2026 — Reported before the open July 30, 2026 (fiscal Q4 and fiscal year ended June 30). Net sales $851.0M (+12.6%), but +9.0% to $679.7M excluding the raw-material surcharge. Operating income a record $206.9M (+36.7%); diluted EPS $3.23 (+46.2%) vs a $3.09 consensus. SAO adjusted operating margin a record 37.8% vs 30.5% — an 18th consecutive quarter of expansion. FY2026 operating income $702.0M, the most profitable year in company history. FY2027 guided $850-880M (+21-25%); FY2029 target $1.2-1.3B. The stock still closed down 5.1% at $503.71, and was $533.91 on August 3. The framing nobody applied: FY2026 net sales ex-surcharge rose $181.4M and Aerospace & Defense alone rose $217.7M. Aerospace contributed 120% of the growth — the other five end markets together shrank $36.3M. Medical, the bull case's counter-cyclical diversifier, fell 24.2% for the year. Second unwritten line: the record margin was not price. SAO shipped 22.6% more pounds while revenue per pound ex-surcharge FELL 9.6%. Absorption, not pricing power. THE CALL: SELL (4/5, AN EXCEPTIONAL BUSINESS AT A PRICE THAT NEEDS THE NEXT DECADE TOO) — base-case value ~$300.0 vs ~$533.91 today. KEY METRICS: - CALL: SELL 4/5 — fair value ~$300 vs $533.91 (-43.8%). DCF on company guidance: FY2027 adj. FCF guided $400-430M, FY2028 ~$665M, FY2029 ~$904M as brownfield capex rolls off. PV of FY2027-31 $3,003M + $11,548M terminal (3.0% growth, 9% discount) = $14,550M EV, less $297.4M net debt, / 50.4M diluted shares = $283. At 9%: bear $198 / base $283 / bull $436, weighted 25/50/25 = $300. Only one of nine cells clears today's price, and it needs the upside case AND an 8% rate on a cyclical. - AEROSPACE WAS 120% OF THE GROWTH: FY2026 net sales ex-surcharge rose $181.4M; Aerospace & Defense alone rose $217.7M ($1,440.7M to $1,658.4M, +15.1%). The other five end markets together went BACKWARDS $36.3M (-4.0%, $905.4M to $869.1M). Medical fell 24.2% for the year ($296.1M to $224.3M) and 29.6% in Q4 ($76.8M to $54.1M); Transportation -10.8%, Distribution -8.1%. A&D is now 65.6% of sales vs 61.4%. Carpenter is CONCENTRATING, not diversifying — the reverse of the bull framing. - THE RECORD MARGIN WAS NOT PRICE: incremental operating margin on ex-surcharge revenue was 99% for the quarter (sales +$56.0M, op income +$55.5M) and 99% for the year (+$181.4M/+$180.2M). But SAO shipped 22.6% more pounds while net sales ex-surcharge PER POUND fell 9.6% ($11.69 to $10.57); total cost per pound fell 13.0% ($10.82 to $9.41) and operating income per pound rose 12.2%. Fixed-cost absorption, not pricing power — it reverses as fast as it repeats. - CASH CONVERSION FALLS AS EARNINGS ACCELERATE: adj. FCF was 54.7% of adj. operating income in FY2025, 51.6% in FY2026 ($362.3M on $702.0M), and the FY2027 guide of $400-430M on $865M is 48.0% — guided FY2027 capex is $355-375M vs $242.7M spent and ~$150M depreciation, ~2.5x D&A. At $533.91 that is 64.8x guided FY2027 FCF, 50.8x trailing EPS of $10.52 and 32x trailing EBITDA. Receivables +22.0% to $701.9M on 8.6% sales growth; DSO 73 to 82 days. - THE HONEST OTHER SIDE, AND THE STREET: 18 straight quarters of SAO margin expansion, adj. operating income up 5x in 3 years ($133M FY23 to $702.0M FY26), net debt $297.4M (~0.35x EBITDA), and an FY2029 target management calls 'not the peak'. On trailing earnings CRS at 50.8x is the CHEAPEST of the aero-materials complex (Howmet ~66x, ATI ~63x): de-rating risk is sector-wide. Street: Buy (14/6/1), consensus $550.60, median $600.00, range $425-$620. We ALIGN on the business, DIFFER on price. What to watch: Bullish: Medical inflecting back to growth repairs the diversification case; brownfield commissioning on time in early FY2028 with capex falling toward the ~$150M depreciation line, which alone takes FY2029 FCF toward $1B; or a raise above the $1.3B FY2029 top end. Bearish: the Oct 22 print at the low end of the guided $195-200M with Medical still falling; capex above $375M or a brownfield slip; or receivables — DSO went 73 to 82 days. Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Episode metadata supplied by the publisher feed · Published Aug 3, 2026

Embed this episode

NOW PLAYING

Carpenter Technology (CRS): Aerospace Was 120% Of The Growth. Is CRS a Buy?

0:00 15:56

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Charged Alpha Stock Encyclopedia?

This episode is 15 minutes long.

When was this Charged Alpha Stock Encyclopedia episode published?

This episode was published on August 3, 2026.

Can I download this Charged Alpha Stock Encyclopedia episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!